

6 April 2020

ASX ANNOUNCEMENT

FIRST PATIENT IN SAVR TRIAL DISCHARGED FROM HOSPITAL

Admedus Limited (ASX:AHZ) (**Admedus** or the **Company**) is pleased to announce that the first patient in its clinical study has been discharged from hospital.

Prof Leon Neethling commented "the patient is doing well with normal gradients upon discharge and had an event free recovery. I am very pleased with the initial results".

"With our first patient who now has normal haemodynamics and an excellent EOA, I am looking forward to seeing more patients enter into the study in the coming weeks and months" he said.

"We are very pleased with the patient's recovery so far and will continue to keep the market updated as and when it's appropriate as study progresses" commented Wayne Paterson CEO

ENDS

About Admedus Limited (ASX: AHZ)

Admedus Ltd is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Its focus is on developing next generation technologies with world class partners.

Authorisation and Additional information

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

For more information:

Ms Kyahn Williamson
WE Communications
E: WE-AUAdmedus@we-worldwide.com
P: +61 401 018 828

www.admedus.com

Twitter: @Admedus

Facebook: www.facebook.com/admedus/

Admedus Limited

Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland 4066

Customer Service:

T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299
E: info@admedus.com W: admedus.com

